Related Experiment Video
Updated: Sep 30, 2025
06:51
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
7.8K
Risdiplam: A Review in Spinal Muscular Atrophy
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. demail@springer.com.
CNS Drugs
|March 14, 2022
Summary
Risdiplam is the first oral medication for spinal muscular atrophy (SMA). Clinical trials show it improves motor function in SMA patients and is well-tolerated.
Area of Science:
- Neurology
- Genetics
- Pharmacology
Background:
- Spinal muscular atrophy (SMA) is a genetic disorder characterized by motor neuron loss.
- The pathophysiology of SMA is driven by a lack of full-length survival motor neuron (SMN) protein.
- Current treatments for SMA aim to increase SMN protein levels.
Purpose of the Study:
- To evaluate the efficacy and safety of risdiplam, an oral SMN2 splicing modifier, for treating SMA.
- To assess motor function improvements and long-term treatment effects of risdiplam in various SMA types.
Main Methods:
- Phase 2/3 clinical trials were conducted.
- Risdiplam was administered to infants and patients aged 2-25 years with SMA types 1, 2, or 3.
- Motor function was assessed, and treatment effects were monitored for up to two years.
Main Results:
- Risdiplam demonstrated significant improvements in motor function in infants with SMA type 1.
- Patients aged 2-25 years with SMA types 2 or 3 also showed significant motor function improvements.
- These motor improvements were sustained with up to two years of risdiplam treatment.
- Risdiplam was generally well-tolerated, exhibiting a favorable benefit-to-risk profile.
Conclusions:
- Risdiplam is an effective oral treatment for SMA across a broad age range and different SMA types.
- Its ability to increase SMN protein production offers a valuable therapeutic option.
- The oral administration of risdiplam enhances treatment convenience for patients with SMA.
